You are here

A Study Of PF-05175157 In Healthy Volunteers

Last updated on May 10, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
South Miami, Florida, 33143 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Type 2 Diabetes Mellitus
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-45 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and/or female (non child-bearing potential) subjects between the ages of
18 and 45 years (inclusive).

- Healthy is defined as no clinically relevant abnormalities identified by a detailed
medical history, full physical examination, including blood pressure and pulse rate
measurements, 12-lead ECG and clinical laboratory tests.

- In addition, subjects must have normal chest x-ray, normal pulmonary function tests
and normal ophthalmological examination.

- Body Mass Index (BMI) of 17.5 to 29.5 kg/m2; and a total body weight > 50 kg (110
lbs).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Evidence or history of clinically significant hematological, renal, endocrine,
gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic
disease (including drug allergies).

- Evidence or history of any chronic ongoing or current pulmonary disease.

- History of smoking in the past 5 years or history or evidence of habitual use of other
(non-smoked) tobacco or nicotine-containing products within 3 months of Screening or
positive cotinine test at Screening or Day 0.

- Active ocular disease including infection, glaucoma, seasonal allergies, dry-eye
symptoms or retinal/optic nerve disease.

- Evidence or history of 'dry eye-syndrome', Meibomian gland disease, ocular
inflammation (eg, uveitis, iritis), chronic blepharitis, any eye surgery including
Lasik, any mechanical injury or chemical exposure to the ocular surface, use of ocular
lubricants, or use of contact lenses.

NCT01274663
Pfizer
Completed
A Study Of PF-05175157 In Healthy Volunteers

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Ovarian Cancer HR+ HER2- Metastatic Breast Cancer
NCT03519178
All Genders
18+
Years
Multiple Sites
Part 1, MELANOMA, SCCHN, OVCA, SARCOMA, OTHER SOLID TUMORS, Part 1 and 2, NSCLC, UROTHELIAL CARCINOMA
NCT02573259
All Genders
18+
Years
Multiple Sites
Diabetes Mellitus, Chronic Obstructive Pulmonary Disease
NCT00138671
All Genders
30+
Years
Multiple Sites
A Study Of PF-05175157 In Healthy Volunteers
A Phase 1 Placebo-Controlled Study To Assess The Safety, Tolerability, And Pharmacokinetics Of PF-05175157 After Administration Of Single Escalating Oral Doses Under Fasted And Fed Conditions In Healthy Volunteers
The primary purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of single oral doses of PF-05175157 in healthy volunteers.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Diabetes Mellitus, Type 2
  • Drug: PF-05175157 or Placebo
    One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
  • Drug: PF-05175157 or Placebo
    One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
  • Experimental: 10 mg PF-05175157 or Placebo
    Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
    Intervention: Drug: PF-05175157 or Placebo
  • Experimental: 30 mg PF-05175157 or Placebo
    Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
    Intervention: Drug: PF-05175157 or Placebo
  • Experimental: 100 mg PF-05175157 or Placebo
    Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
    Intervention: Drug: PF-05175157 or Placebo
  • Experimental: 300 mg PF-05175157 or Placebo
    Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
    Intervention: Drug: PF-05175157 or Placebo
  • Experimental: 600 mg PF-05175157 or Placebo
    Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
    Intervention: Drug: PF-05175157 or Placebo
  • Experimental: 800 mg PF-05175157 or Placebo
    Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
    Intervention: Drug: PF-05175157 or Placebo
  • Experimental: xxx mg PF-05175157 or Placebo
    Subjects will receive one dose of PF-05175157 or one dose of Placebo (2:1 ratio) in random order.
    Intervention: Drug: PF-05175157 or Placebo
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
63
May 2011
May 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male and/or female (non child-bearing potential) subjects between the ages of 18 and 45 years (inclusive).
  • Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurements, 12-lead ECG and clinical laboratory tests.
  • In addition, subjects must have normal chest x-ray, normal pulmonary function tests and normal ophthalmological examination.
  • Body Mass Index (BMI) of 17.5 to 29.5 kg/m2; and a total body weight > 50 kg (110 lbs).

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies).
  • Evidence or history of any chronic ongoing or current pulmonary disease.
  • History of smoking in the past 5 years or history or evidence of habitual use of other (non-smoked) tobacco or nicotine-containing products within 3 months of Screening or positive cotinine test at Screening or Day 0.
  • Active ocular disease including infection, glaucoma, seasonal allergies, dry-eye symptoms or retinal/optic nerve disease.
  • Evidence or history of 'dry eye-syndrome', Meibomian gland disease, ocular inflammation (eg, uveitis, iritis), chronic blepharitis, any eye surgery including Lasik, any mechanical injury or chemical exposure to the ocular surface, use of ocular lubricants, or use of contact lenses.
Sexes Eligible for Study: All
18 Years to 45 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01274663
B1731001
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
October 2011

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now